Vertex Pharmaceuticals Incorporated
VRTX · Nasdaq
- $496.07
- $132.79B
- Open
- —
- —
- $519.82 - $546.17
- $362.50 - $533.67
- —
- —
- 2.68M
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops and sells medicines, with its cystic-fibrosis franchise providing the largest share of revenue and newer products contributing an increasing portion. Its portfolio is expanding through launches and pipeline programs, including a near-term renal opportunity and the Crinetics acquisition. Vertex makes money primarily from pharmaceutical product sales to patients through healthcare providers, payers and distribution channels. The company generated $12.0 billion of revenue and $4.0 billion of net income in fiscal 2025, compared with $11.0 billion of revenue and a $0.5 billion net loss in 2024; second-quarter 2026 revenue was $3.3 billion.
Notable Price Movement
- Aug 3-7$496.073.98%
Vertex fell $11.69, or 2.38%, from $490.39 to $478.70 over the week. The stock declined for four consecutive sessions, reaching $470.72 on August 3, before rebounding 1.7% on August 4 on reaction to its second-quarter results. The earnings report delivered mixed signals: revenue rose 12% year over year to $3.3 billion and beat estimates by 3.32%, while earnings missed estimates by 1.25%. Vertex nevertheless raised its 2026 sales outlook, citing cystic-fibrosis growth, increasing contributions from newer products and a near-term renal launch. The rebound recovered part of the pre-earnings slide but left the stock below its starting level, with Crinetics integration risk also weighing on the outlook.
Stories & Analysis
S&P 500 Movers: COHR, HONIVVertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know
